8
Supporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route of PEG-b-P((LL-g-TK-PTX)-(LL-g-DMA)).

Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Supporting information

A pH-responsive charge-reversal drug delivery system with

tumor-specific drug release and ROS generation for cancer

therapy

Scheme S1. Synthesis route of PEG-b-P((LL-g-TK-PTX)-(LL-g-DMA)).

Page 2: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S1 1H NMR spectrum of TK in CDOD3.

Page 3: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S2 1H NMR spectrum of TK in DMSOd6.

Page 4: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S3 Liner ion trap mass spectrum of TK-PTX record in a

Page 5: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S4 Hemolysis rate of PVD-NPs, PD-NPs, and PVS-NPs.

Page 6: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S5 Mean fluorescence intensity (MFI) analyzed by flow cytometry of DCF signal in NIH-3T3 cells after treated with PD-NPs, VK3, PVD-NPs, and PVD-NPs + DIC.

Page 7: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S6 Cytotoxicity of PTX, VK3, PTX+VK3, PVD-NPs, and PD-NPs against NIH-3T3 cells. Data showed as mean ± SD, n = 6.

Page 8: Web viewSupporting information A pH-responsive charge-reversal drug delivery system with tumor-specific drug release and ROS generation for cancer therapy Scheme S1. Synthesis route

Fig. S7 Images of H&E staining of major organs sections, the images were acquired at 20× objective.